Quote | Alpha Tau Medical Ltd. (NASDAQ:DRTS)
Last: | $2.23 |
---|---|
Change Percent: | 0.0% |
Open: | $2.39 |
Close: | $2.23 |
High: | $2.39 |
Low: | $2.2 |
Volume: | 3,710 |
Last Trade Date Time: | 07/03/2024 03:00:00 am |
News | Alpha Tau Medical Ltd. (NASDAQ:DRTS)
The pooled analysis included data from 4 i nternational clinical trials spanning a n array of hard-to-treat indications including skin, head & neck, and oral cavity. Initial response data demonstrated an overall response rate of almost 100% in tre...
2024-05-21 10:00:22 ET Jason Bednar from Piper Sandler issued a price target of $7.00 for DRTS on 2024-05-21 08:51:00. The adjusted price target was set to $7.00. At the time of the announcement, DRTS was trading at $2.91. The overall price target consensus is at $12.00 ...
Message Board Posts | Alpha Tau Medical Ltd. (NASDAQ:DRTS)
Subject | By | Source | When |
---|---|---|---|
New buy rating | theswordman | investorshub | 04/25/2023 5:31:44 AM |
swordman: 1st patient enrolled in DRTS pancreatic cancer trial https://www.alphatau.com/single-post/ | swordman | investorshangout | 04/03/2023 4:45:38 PM |
Alpha Tau enrolled the 1st patrient in their | theswordman | investorshub | 04/03/2023 4:43:55 PM |
swordman: New video https://youtu.be/rLgMmDbJxJ8 | swordman | investorshangout | 03/19/2023 10:08:22 PM |
New video | theswordman | investorshub | 03/19/2023 10:07:25 PM |
News, Short Squeeze, Breakout and More Instantly...
Alpha Tau Medical Ltd. Company Name:
DRTS Stock Symbol:
NASDAQ Market:
Alpha Tau Medical Ltd. Website:
The pooled analysis included data from 4 i nternational clinical trials spanning a n array of hard-to-treat indications including skin, head & neck, and oral cavity. Initial response data demonstrated an overall response rate of almost 100% in tre...
2024-05-21 10:00:22 ET Jason Bednar from Piper Sandler issued a price target of $7.00 for DRTS on 2024-05-21 08:51:00. The adjusted price target was set to $7.00. At the time of the announcement, DRTS was trading at $2.91. The overall price target consensus is at $12.00 ...
JERUSALEM, May 21, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, today announced that CFO Raphi Levy will present a corporate overview an...